References
- 1. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press. 2004;p.54-5.
- 2. YE. Nikiforov, Paul W. Biddinger, Lester D.R. Thompson. Diagnostic Pathology and Molecular Genetics of the Thyroid Second Edition- Chapter 7 - Thyroid Tumors: Classification, Staging and General Considerations, Chapter 11- Papillary Carcinoma, Lippincott Williams & Wilkins. 2012;108-118,183-243.
- 3. Kahn C, Simonella L, Sywak M, et al. Postsurgical pathology reporting of thyroid cancer in New South Wales, Australia. Thyroi. 2012;(22):604-10.
- 4. Davies L, Welch HG. Current Thyroid Cancer Trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-322.
- 5. Kent WD, Hall SF, Isotalo PA, et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007; (177):1357-61.
- 6. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;(144):980-8.
- 7. Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;(21):231-236.
- 8. Furio Pacini. Thyroid microcarcinoma. Best Practice & Research Clinical Endocrinology & Metabolism. 2012;421-429.
- 9. Grodski S, Brown T, Sidhu S, et al. Increased incidence of thyroid cancer is due to increased pathologic detection. Surgery. 2008;(144):1038-43.
- 10. Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: The role of endocrinologists and ultrasounds. Thyroid. 2014;24(3):472-479.
- 11. Furio Pacini . Management of Papillary Thyroid Microcarcinoma: Primum Non Nocere! J Clin Endocrinol Metab. 2013;98(4):1391-1393.
- 12. Kitahara CM, Platz EA, Beane Freeman LE, et al. Physical activity, diabetes, and thyroid cancer risk: A pooled analysis of five prospective studies. Cancer Causes & Control. 2012;23(3):463-71.
- 13. Howlander N, Noone AM, Krapcho M, et al. J. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
- 14. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;(14):1056-1060.
- 15. Roti E, degli Uberti EC, Bondanelli M, et al. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008;(159):659-673.
- 16. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, et al. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;(71):4022-4029.
- 17. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer 1985;(56):531-538.
- 18. Kovacs GL, Gonda G, Vadasz G, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid. 2005;(15):152-7.
- 19. Sakorafas GH, Stafyla V, Kolettis T, et al. Microscopic papillary thyroid cancer as an incidental finding in patient treated surgically for presumably benign thyroid disease. Journal of Postgraduate Medicine. 2007;(53):23-26.
- 20. De Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series. Endocrine Pathology. 2006;(17):165-173.
- 21. Neuhold N, Schultheis A, Hermann M. Incidental papillary microcarcinoma of the thyroid-further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann Surg Oncol. 2011;(18):3430.
- 22. Piana S, Ragazzi M, Tallini G, et al. Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis. Hum Pathol. 2013;44(4):556-565.
- 23. Malandrino P, Pellegriti G, Attard M, et al. Papillary thyroid microcarcinomas:a comparative study of the characteristics and risk factors at presentation in two cancer registries. JClin Endocrinol Metab. 2013;(98):1427-1434.
- 24. Besic N, Pilko G, Petric R, et al. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol. 2008;(97):221-5.
- 25. Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;(254):653-660.
- 26. Robenshtok E, Grewal RK, Fish S, et al. A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. Thyroid. 2013;23(4):436-442.
- 27. Moon HJ, Kim EK, Chung WY. Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? Ann Surg Oncol. 2011;(18):1916-23.
- 28. Zhang L, Wei WJ, Ji QH, et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012;(97):1250-1257.
- 29. Kim BY, Jung CH, Kim JW, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Med J. 2012;(53):924-930.
- 30. Zhao Q, Ming J, Liu C, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol. 2013;(20):746-52.
- 31. Elisei R, Viola D, Torregrossa L,et al. The BRAF (V600E) mutation is an independent, poor prognostic factor for the outcome of patients with lowrisk intrathyroid papillary thyroid carcinoma: single institution results from a large cohort study. J Clin Endocrinol Metab. 2012;(97):4390-4398.
- 32. Virk RK, Van Dyke AL, Finkelstein A, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol. 2013;26(1):62-70.
- 33. Berger N, Borda A. Pathologie thyroidienne, parathyroidienne et surrenalienne- Techniques d`etude des lesions thyroidienne. Editura Sauramps Medical Montpellier. 2010;(366):29-33.
- 34. Nikiforov YE, Biddinger PW, Thompson LDR. Diagnostic Pathology and Molecular Genetics of the Thyroid Second Edition - Chapter 19 - Gross Examination, Lippincott Williams & Wilkins. 2012;403-409.
- 35. Sobin LH, Gospodarowicz MK, Wittekind C. UICC TNM Classification of Malignant Tumours. 7th ed. Wiley-Liss; New York NY: 2009.
- 36. Friguglietti CU, Dutenhefner SE, Brandao LG, et al. Classification of papillar thyroid microcarcinoma according to the size and fine-needle aspiration cytology: behavior and therapeutic implications. Head Neck. 2011;(33):696-701.
- 37. Buffet C, Golmard JL, Hoang C, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol. 2012;(167):267-275.
- 38. Ross DS, Litofsky D, Ain KB, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009;(19):1043-8.
- 39. Kim K, Kim S, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: A retrospective study of 2,309 consecutive patients. Annals of Surgical Oncology. 2015;22(1):125-31.
- 40. Ortiz Sebastian S, Rodriguez Gonazles JM, Parilla Paricio P, et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg. 2000;(135):272-277